Omnimmune Holdings

OMMH

Biotechnology · Healthcare

Price

$0.00

-0.00 (-0.00%)

Market Cap

$981

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Share count falling — buybacks

−15.9% over 2y

The company has reduced its share count over this period, returning value to shareholders through buybacks.

Diluted shares outstanding: 10.5M (2007) → 8.8M (2009)

Omnimmune Holdings, Inc. is a small biotechnology company focused on developing treatments that work with the immune system to fight disease. The company is in the early stages of research and development, meaning it does not yet sell products to patients or generate meaningful revenue. It operates in the healthcare sector alongside other early-stage biotech firms working on immunology-based therapies.

Like most early-stage biotechs, Omnimmune does not currently earn revenue from product sales. Instead, it relies on funding from investors and potentially grants or partnerships to keep its research going. The company has a very small market capitalization, and its financial margins reflect a business that is spending money on development without yet bringing in sales. The main risk is that drug development is expensive, takes many years, and most experimental treatments never reach approval — meaning the company faces significant uncertainty about whether its science will ever become a commercial product.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

+40.0% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$0/ year

Research and development spending

Insider Activity

96.6%ownership

→ Flat

Insiders holding steady — not selling despite ability to

Cash Runway

~0 months

$4,805 cash & investments

Short runway — potential dilution ahead through share issuance

Cash watch

Omnimmune Holdings has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

N/A

—

Data not available

Operating Margin

N/A

—

Data not available

ROCE

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

N/A

Data not available

EPS YoY

N/A

—

Data not available

EPS Consistency

0/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

—

Data not available

FCF Margin

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

N/A

—

Data not available

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial